Liposomal amphotericin B as a treatment for human leishmaniasis

Lignende værker

• High Mortality among Older Patients Treated with Pentavalent Antimonials for Visceral Leishmaniasis in East Africa and Rationale for Switch to Liposomal Amphotericin B
  af: Chappuis, François, et al.
  Udgivet: (2011)
• Five-Year Field Results and Long-Term Effectiveness of 20 mg/kg Liposomal Amphotericin B (Ambisome) for Visceral Leishmaniasis in Bihar, India
  af: Burza, Sakib, et al.
  Udgivet: (2014)
• Risk Factors for Visceral Leishmaniasis Relapse in Immunocompetent Patients following Treatment with 20 mg/kg Liposomal Amphotericin B (Ambisome) in Bihar, India
  af: Burza, Sakib, et al.
  Udgivet: (2014)
• Post Kala-Azar Dermal Leishmaniasis following Treatment with 20 mg/kg Liposomal Amphotericin B (Ambisome) for Primary Visceral Leishmaniasis in Bihar, India
  af: Burza, Sakib, et al.
  Udgivet: (2014)
• Effectiveness and Safety of Liposomal Amphotericin B for Visceral Leishmaniasis under Routine Program Conditions in Bihar, India
  af: Sinha, Prabhat K., et al.
  Udgivet: (2010)